Cargando…

The Efficacy of Immune Checkpoint Inhibitors vs. Chemotherapy for KRAS-Mutant or EGFR-Mutant Non-Small-Cell Lung Cancers: A Meta-Analysis Based on Randomized Controlled Trials

OBJECTIVE: To assess and compare the effectiveness of immune checkpoint inhibitors vs. chemotherapy for KRAS-mutant or EGFR-mutant non-small-cell lung cancers. METHODS: Until February 19, 2022, Cochrane Library, PubMed, Web of Science, and Embase were searched for relevant randomized controlled tria...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Wei, Li, Ling, Cheng, Sheng, Yu, Junxian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9439907/ https://www.ncbi.nlm.nih.gov/pubmed/36061356 http://dx.doi.org/10.1155/2022/2631852

Ejemplares similares

Resistance to immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer
por: Li, Yunchang, et al.
Publicado: (2022)

Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis
por: Qian, Xiaoyu, et al.
Publicado: (2022)

Efficacy of immune checkpoint inhibitors in patients with KRAS-mutant advanced non-small cell lung cancer: A retrospective analysis
por: Gu, Xiaodong, et al.
Publicado: (2023)

Small molecular inhibitors for KRAS-mutant cancers
por: Wu, Xuan, et al.
Publicado: (2023)

Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench
por: Jin, Rui, et al.
Publicado: (2020)

Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
por: Wiest, Nathaniel, et al.
Publicado: (2021)

KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition
por: Adderley, Helen, et al.
Publicado: (2019)

YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer
por: Li, Ling-Chen, et al.
Publicado: (2023)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2020)

Treatment-Related Adverse Events of Combination EGFR Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor in EGFR-Mutant Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Chan, Daisy Wai-Ka, et al.
Publicado: (2022)

Let-7 Sensitizes KRAS Mutant Tumor Cells to Chemotherapy
por: Dai, Xin, et al.
Publicado: (2015)

Severe Immune Checkpoint Inhibitor Hepatitis in KRAS G12C-Mutant NSCLC Potentially Triggered by Sotorasib: Case Report
por: Begum, Parvin, et al.
Publicado: (2021)

Expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed small cell lung cancer
por: Zhang, Shi-Ling, et al.
Publicado: (2023)

Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade
por: Umelo, Ijeoma Adaku, et al.
Publicado: (2015)

Efficacy and Safety of Neoadjuvant Targeted Therapy vs. Neoadjuvant Chemotherapy for Stage IIIA EGFR-Mutant Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Chen, Dong, et al.
Publicado: (2021)

Influence of EGFR-activating mutations on sensitivity to tyrosine kinase inhibitors in a KRAS mutant non-small cell lung cancer cell line
por: Tsukumo, Yoshinori, et al.
Publicado: (2020)

The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation
por: Jeong, Sun Young, et al.
Publicado: (2023)

BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer
por: Fan, Fushun, et al.
Publicado: (2020)

Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysis
por: Zhang, Chao, et al.
Publicado: (2022)

Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer
por: Choughule, A, et al.
Publicado: (2014)

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
por: Pang, Xiufeng, et al.
Publicado: (2016)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC
por: Chen, Ya, et al.
Publicado: (2021)

Associations of immune checkpoint inhibitor therapy efficacy with clinical parameters and tumor‑infiltrating CD68‑positive cell counts in patients with EGFR‑mutant non‑small cell lung cancer
por: Tsuda, Takeshi, et al.
Publicado: (2023)

A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC
por: Morimoto, Kenji, et al.
Publicado: (2022)

Defeat mutant KRAS with synthetic lethality
por: Pang, Xiufeng, et al.
Publicado: (2016)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

Clinical characteristics and outcomes of Chinese patients with KRAS‐mutant non‐small cell lung cancer after chemotherapy
por: Zheng, Yawen, et al.
Publicado: (2021)

Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants
por: Greulich, Heidi, et al.
Publicado: (2005)

Influence of PD‐L1 expression on the efficacy of EGFR‐TKIs in EGFR ‐mutant non‐small cell lung cancer
por: Lei, Si‐Yu, et al.
Publicado: (2023)

Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts
por: Rosen, Joshua C., et al.
Publicado: (2021)

Selective targeting of KRAS-Mutant cells by miR-126 through repression of multiple genes essential for the survival of KRAS-Mutant cells
por: Hara, Toshifumi, et al.
Publicado: (2014)

Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of KRAS-mutant colorectal cancer
por: Zhou, Xinyi, et al.
Publicado: (2022)

Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors
por: Ribeiro Gomes, Jéssica, et al.
Publicado: (2015)

Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer
por: Shen, Chia-I, et al.
Publicado: (2021)

Oxaliplatin-Based Chemotherapy Is More Beneficial in KRAS Mutant than in KRAS Wild-Type Metastatic Colorectal Cancer Patients
por: Lin, Yu-Lin, et al.
Publicado: (2014)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

KRAS mutant colorectal tumors: Past and present
por: Brand, Toni M., et al.
Publicado: (2012)

Distinct metabolic preference of atypical KRAS mutant
por: Cheong, Heesun
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_namdddvhc23e9nlpv29uhrc402